Teva Pharma purchases facilities in Pennsylvania R&D campus

Teva Pharma purchases facilities in Pennsylvania for R&D campus

10:08 AM, 12th July 2019
Teva Pharma logo

PARSIPPANY, US: Teva Pharmaceuticals USA Inc has completed the purchase of three buildings on Brandywine Parkway in West Chester, Pennsylvania.

Together with three other buildings Teva owns in the same corporate park, firmly establishes a North America Research & Development (R&D) campus.

Focused primarily on biologics, a core R&D platform on which the company continues to build for future growth, the R&D campus further augments the company’s significant US presence.

Representing a significant investment over the last 12 years in capital improvements, infrastructure and now the purchase of these three buildings, Teva’s West Chester R&D campus houses clinical development and manufacturing processes for highly complex biologic medicines developed by Teva.

The campus also includes laboratories where advanced preclinical and clinical testing is conducted to ensure the safety and effectiveness of new drugs. Approximately 650 employees will be based at Teva in West Chester by the end of 2019, including teams involved in combination product and device R&D, regulatory affairs, medical affairs, and support functions.

Teva employs approximately 7,000 employees in multiple locations in the US in manufacturing, commercial, R&D and administrative functions.

“With our late-stage biologics R&D development teams co-located on a single campus, the company has created a one-stop shop for biologics development and clinical manufacturing. From cell bank to syringe, our West Chester R&D campus is home to many of the North American-based R&D teams and processes that will bring more biologics treatment options to patients, and support Teva’s global mission to improve lives,” said Mehran Yazdanian, Senior Director, Specialty R&D Scientific Strategy & Operations, Global R&D and Site Head.

© Worldofchemicals News

0 Comments

Login

Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News


McDermott starts world's largest catalytic dehydrogenation plant

HOUSTON, US: McDermott International Inc announced the recent successful startup of the world's largest catalytic dehydrogenation plant, which is loca ...

Read more
AGM achieves progress in development of anti-corrosion coatings

LONDON, UK: Applied Graphene Materials, the producer of specialty graphene materials has achieved significant technological progress (patent pending) ...

Read more
Assam Gas, Oil India & GAIL sign pact for setting up new CGD company

GUWAHATI, INDIA: Assam Gas Company Ltd (AGCL), Oil India Limited (OIL) and GAIL Gas Ltd has signed a joint venture agreement for incorporating a new c ...

Read more
Indian researchers develop sustainable paints using litchi extracts

PUNJAB, INDIA: Increasing use of synthetic paints has over the years become a cause for worry with the World Health Organization (WHO) reporting a 20- ...

Read more
McDermott wins $1.5 bn EPCI mega-project by Saudi Aramco

HOUSTON, US: McDermott International Inc has been awarded a contract in excess of $1.5 billion for Package 4 of Saudi Aramco's Marjan Increment Develo ...

Read more
Glenmark, Torrent Pharma sign deal to co-market diabetes drug in India

MUMBAI, INDIA: Glenmark Pharmaceuticals Ltd and Torrent Pharmaceuticals Limited have entered into a non-exclusive sub-licensing agreement to co-market ...

Read more
www.worldofchemicals.com uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X